Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label
Registrational Phase 3 Study
.
Show all posts
Showing posts with label
Registrational Phase 3 Study
.
Show all posts
Wednesday, March 20, 2019
Theravance Biopharma Announces First Patient Dosed in Registrational Phase 3 Study of Ampreloxetine (TD-9855) for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
›
Theravance Biopharma, Inc. (NASDAQ: TBPH) ("Theravance Biopharma" or the "Company") announced dosing of the first ...
›
Home
View web version
